logo BDSP

Base documentaire

  1. Management of NSAID-induced gastropathy : An economic decision analysis.

    Article - En anglais

    The use of nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with a 2% to 4% annual incidence of serious gastrointestinal complications.

    These adverse clinical outcomes, and the strategies used to prevent their occurrence, translate into a significant economic burden.

    A decision-analysis model was constructed to contrast the 6-month costs associated with various approaches to preventing and managing NSAID-induced gastropathy and to evaluate the economic impact of two treatment regimens using fixed-dose formulations of diclofenac/misoprostol.

    After incorporating expected medical outcomes and predicted practice patterns, 6-month per-patient costs were derived from the model for each of five treatment regimens :

    • (1) NSAID alone ;

    • (2) NSAID with a histamine2-receptor antagonist ;

    • (3) NSAID with coprescribed misoprostol ;

    • (4) diclofenac/misoprostol 50 mg/200 mug TID/BID ;

    • and (5) diclofenac/misoprostol 75 mg/200 mug BID.

    The combined diclofenac/misoprostol regimens demonstrated an 18.6% per-patient cost advantage compared with the combined NSAID regimens.

    Based on a 6-month period, this cost savings translated into a $214.00 per-patient overall cost savings ($1153.00 per patient for NSAID regimens versus $939.00 for diclofenac/misoprostol regimens).

    The magnitude of this difference was verified by Monte Carlo simulation. (...)

    Mots-clés Pascal : Diclofénac, Analgésique, Misoprostol, Antisécrétoire, Antiulcéreux, Effet secondaire, Estomac pathologie, Homme, Gastrite, Analyse économique, Economie santé, Prévalence, Modèle, Aide décision, Analyse avantage coût, Etude comparative, Association médicamenteuse, Antiinflammatoire non stéroïde, Toxicité, Arylacétique acide dérivé, Prostaglandine dérivé, Appareil digestif pathologie

    Mots-clés Pascal anglais : Diclofenac, Analgesic, Misoprostol, Antisecretory agent, Antiulcer agent, Secondary effect, Gastric disease, Human, Gastritis, Economic analysis, Health economy, Prevalence, Models, Decision aid, Cost benefit analysis, Comparative study, Drug combination, Non steroidal antiinflammatory agent, Toxicity, Arylacetic acid derivatives, Prostaglandin derivatives, Digestive diseases

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 98-0098060

    Code Inist : 002B02L. Création : 22/06/1998.